Alentis Therapeutics
Alentis is developing treatments for fibrotic disease and associated cancer by exploiting Claudin-1 (CLDN1) and its associated pathways.
Enyo Pharma
Biomimetics for Liver Disorders
Targeting the biochemical pathways underlying behind virus-host interactions, Enyo Pharma is developing a novel class of non-bile acid FXR agonists for the treatment of Hepatitis B and nonalcoholic steatohepatitis (fatty liver disease).
Enyo's lead candidate, EYP001, has shown promising results in patients in both indications and has demonstrated a differentiated safety profile compared to other FXR agonists. This compound is currently in Phase 2 clinical trials.